Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Trovagene Inc (NASDAQ:TROV)

2.50
Delayed Data
As of Dec 09
 -0.15 / -5.66%
Today’s Change
2.30
Today|||52-Week Range
6.93
-53.70%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$76.5M

Company Description

Trovagene, Inc. is a molecular diagnostic company, which focuses on the development and commercialization of a proprietary urine-based molecular diagnostic technology for use in disease detection and monitoring across a variety of medical disciplines. Its focus is to leverage its novel cell-free molecular diagnostic platform to facilitate improvements in the field of oncology, while its external focus includes developing collaborations in the areas of infectious disease, transplant medicine and prenatal diagnostics. The company's proprietary urine-based molecular diagnostic tests are designed to detect specific nucleic acids in urine which are known as transrenal DNA and RNA. Its technology is applied in various testing, such as tumor detection and monitoring, prenatal genetic testing, infectious diseases, tissue transplantation, and forensic identification, as well as for patient selection in clinical trials. Trovagene was founded by Gabriel M. Cerrone, L. David Tomei, Samuil Umansky and Hovsep Melkonyan on August 4, 1999 and is headquartered in San Diego, CA.

Contact Information

TrovaGene, Inc.
11055 Flintkote Avenue
San Diego California 92121
P:(858) 952-7570
Investor Relations:

Employees

Shareholders

Mutual fund holders8.51%
Other institutional18.75%
Individual stakeholders15.94%

Top Executives

Bill WelchChief Executive Officer & Director
Elizabeth AndersonVice President-Finance & Administration
Mark ErlanderChief Scientific Officer
Karsten SchmidtChief Technology Officer
Janel DockterVice President-Product Development